ethyl (S)-3-amino-3-(2-thienyl)propanoate | 247045-68-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl (S)-3-amino-3-(2-thienyl)propanoate
• 英文别名: Ethyl (3S)-3-amino-3-(thiophen-2-YL)propanoate；ethyl (3S)-3-amino-3-thiophen-2-ylpropanoate
• CAS: 247045-68-7
• 化学式: C₉H₁₃NO₂S
• mdl: MFCD02663319
• 分子量: 199.274
• InChiKey: XYBONARLWNRZCA-ZETCQYMHSA-N

物化性质

• 沸点：
  305.5±32.0 °C(Predicted)
• 密度：
  1.178±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  80.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl (S)-3-amino-3-(2-thienyl)propanoate 在 N-甲基吗啉 、 盐酸 、 lithium hydroxide 、 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 作用下， 以 乙腈 为溶剂， 生成 N-3-(4-piperidinepropionyl)-(R)-(-)-nipecotyl[(S)-3-amino-3-(2-thienyl)]propionic acid
  参考文献：
  名称：

  Solid-phase parallel synthesis applied to lead optimization: Discovery of potent analogues of the GPIIb/IIIa antagonist RWJ-50042

  摘要：

  A study of beta-turn peptide mimetics, related to the C-terminal gamma-chain of fibrinogen and containing a nipecotic acid scaffold, led to RWJ-50042 (1), an interesting fibrinogen receptor (GPIIb/IIIa) antagonist. To enhance potency, we employed solid-phase parallel synthesis for the preparation of over 200 analogues in a protocol of optimization cycles. This strategy produced several promising nipecotamide analogues, such as 25, which is 35 times more potent than 1 in vitro. Copyright (C) 1996 Elsevier Science Ltd.

  DOI：

  10.1016/0960-894x(96)00438-6
• 作为产物：
  描述：

  ethyl (E)-3-(thiophen-2-yl)acrylate 在 palladium dihydroxide 正丁基锂 、 三甲基氯硅烷 、 R(+)-alpha-甲基苄胺 、 氢气 作用下， 生成 ethyl (S)-3-amino-3-(2-thienyl)propanoate
  参考文献：
  名称：

  Solid-phase parallel synthesis applied to lead optimization: Discovery of potent analogues of the GPIIb/IIIa antagonist RWJ-50042

  摘要：

  A study of beta-turn peptide mimetics, related to the C-terminal gamma-chain of fibrinogen and containing a nipecotic acid scaffold, led to RWJ-50042 (1), an interesting fibrinogen receptor (GPIIb/IIIa) antagonist. To enhance potency, we employed solid-phase parallel synthesis for the preparation of over 200 analogues in a protocol of optimization cycles. This strategy produced several promising nipecotamide analogues, such as 25, which is 35 times more potent than 1 in vitro. Copyright (C) 1996 Elsevier Science Ltd.

  DOI：

  10.1016/0960-894x(96)00438-6

文献信息

• Chiral Lewis Base-Catalyzed, Enantioselective Reduction of Unprotected β-Enamino Esters with Trichlorosilane
  作者：Jianheng Ye、Chao Wang、Lin Chen、Xinjun Wu、Li Zhou、Jian Sun

  DOI：10.1002/adsc.201501061

  日期：2016.3.31

  reduction of N‐unsubstituted β‐enamino esters represents a major challenge for asymmetric catalysis. In this paper, the first organocatalytic system that could be used for the asymmetric hydrosilylation of N‐unsubstituted β‐enamino esters has been developed. Using N‐tert‐butylsulfinyl‐L‐proline‐derived amides and L‐pipecolinic acid‐derived formamides as catalyst, a broad range of β‐aryl‐ and β‐alkyl‐substituted

  N-未取代的β-烯胺酯的催化不对称还原是不对称催化的主要挑战。在本文中，开发了第一个可用于N-未取代的β-烯氨基酯不对称氢化硅烷化的有机催化体系。使用ñ -叔-butylsulfinyl-大号脯氨酸衍生的酰胺和大号-pipecolinic酸衍生甲酰胺作为催化剂，广泛β -芳基-和β-烷基取代的游离β氨基酯可以以高产率制备，并且对映选择性。（R）-3-氨基-3-苯基丙酸乙酯和异丙基（S）-3-氨基-4-（2,3,5-三氟苯基）丁酸酯。所得产品可以通过短合成途径顺利转化为FDA批准的药物达泊西汀和西他列汀。
• Candida antarctica lipase A—a powerful catalyst for the resolution of heteroaromatic β-amino esters
  作者：Magdolna Solymár、Ferenc Fülöp、Liisa T. Kanerva

  DOI：10.1016/s0957-4166(02)00637-7

  日期：2002.10

  Enantioselective acylations of 3-amino-3-beteroarylpropanoates (ArCH(NH2)CH2CO2Et; Ar = 2- or 3-thienyl or -furyl) were performed in the presence of Candida antarctica lipase A. As a result of the excellent chemo- and enantioselectivities (E > 100), gram-scale resolutions were carried out in ethyl butanoate. The hydrochloride salts of the unreacted R substrates and the butanamides of the reactive S enantiomers were thus prepared. (C) 2002 Elsevier Science Ltd. All rights reserved.
• N,N-DISUBSTITUTED AMIDES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS
  申请人：ENCYSIVE PHARMACEUTICALS, INC

  公开号：EP1071680B1

  公开（公告）日：2008-07-23
• Solid-phase parallel synthesis applied to lead optimization: Discovery of potent analogues of the GPIIb/IIIa antagonist RWJ-50042
  作者：William J. Hoekstra、Bruce E. Maryanoff、Patricia Andrade-Gordon、Judith H. Cohen、Michael J. Costanzo、Bruce P. Damiano、Barbara J. Haertlein、Bruce D. Harris、Jack A. Kauffman、Patricia M. Keane、David F. McComsey、Frank J. Villani、Stephen C. Yabut

  DOI：10.1016/0960-894x(96)00438-6

  日期：1996.10

  A study of beta-turn peptide mimetics, related to the C-terminal gamma-chain of fibrinogen and containing a nipecotic acid scaffold, led to RWJ-50042 (1), an interesting fibrinogen receptor (GPIIb/IIIa) antagonist. To enhance potency, we employed solid-phase parallel synthesis for the preparation of over 200 analogues in a protocol of optimization cycles. This strategy produced several promising nipecotamide analogues, such as 25, which is 35 times more potent than 1 in vitro. Copyright (C) 1996 Elsevier Science Ltd.